About Talphera, Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.
Quality Assessment
Talphera, Inc. is a high-risk healthcare company with a Compass Score of 0. Poor quality metrics and high risk. Not one for conservative investors.
Score Breakdown
The Compass Score is based on 6 quality factors identified by academic research.
Click any factor to see detailed metrics
Valuation Metrics
Click any metric for details
Catalyst Signal
PlusRecent earnings beats and analyst-upgrade momentum. How it works
Analyst Track Record
Financial Health
PlusClick any metric for details
Growth Projections
PlusTechnical Overview
Click any metric for details
Similar High-Quality Stocks
LXRX
Lexicon Pharmaceuticals, Inc.
MRVI
Maravai LifeSciences Holdings, Inc.
BLLN
BillionToOne, Inc.
DAWN
Day One Biopharmaceuticals, Inc.
IDYA
IDEAYA Biosciences, Inc.
ENTO
Entero Therapeutics, Inc.
Important Disclaimer
The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.
Unlock Detailed Metrics
Upgrade to Plus to see the actual financial values behind each quality factor.
- See exact ROA, cash flow ratios, and more
- Unlimited stock views + smart search
- Export data to CSV
- Golden Stocks + analyst coverage
Cancel anytime